MASLD Biomarker Panels for Molecular Subtype Classification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The high heterogeneity of metabolic dysfunction-associated fatty liver disease (MASLD) poses challenges for accurate diagnosis and treatment, as existing classification models fail to account for the variability in patient susceptibility due to factors like age, genotype, and lifestyle, leading to ineffective treatments such as Resmetirom and OCA/fenofibrate.
Innovation Solution
A biomarker-based classification system is developed, comprising combinations of liver, serum, and urine protein and metabolite biomarkers, which categorize MASLD into metabolically active, high-risk cirrhosis, and high-risk hepatocellular carcinoma types, providing a more accurate molecular classification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing classification models (BMI-based, PNPLA3-based) are used to categorize MASLD patients, then the classification process is simple and easy to implement, but the classification accuracy is insufficient due to high heterogeneity and inability to account for multiple risk factors
Solution Approach 1:
The patent segments MASLD classification into multiple molecular subtypes (MASLD-1, MASLD-2, MASLD-3) based on distinct gene expression profiles and biomarker patterns. Each subtype represents a specific molecular phenotype with unique pathogenic mechanisms, allowing precise stratification of heterogeneous MASLD patients beyond simple BMI or single-gene classifications.
Solution Approach 2:
The patent employs a composite classification approach integrating multiple types of data: gene expression profiles, serum biomarkers (lipidomics, proteomics), and clinical parameters. This multi-dimensional composite model captures the complexity of MASLD heterogeneity by combining molecular, metabolic, and clinical information into a unified classification system.
2Reliability
If Resmetirom is administered to all MASLD patients regardless of subtype, then the treatment coverage is comprehensive, but the therapeutic effectiveness is low because the drug only benefits a specific subset of patients
Solution Approach 1:
The patent identifies that Resmetirom specifically benefits MASLD-1 patients who exhibit characteristic gene expression profiles and biomarker patterns. By assigning different treatment strategies to different molecular subtypes (e.g., Resmetirom for MASLD-1, alternative therapies for MASLD-2 and MASLD-3), the treatment approach achieves local optimization where each patient receives therapy matched to their specific molecular phenotype.
Solution Approach 2:
The patent uses gene expression levels and biomarker concentrations as key parameters to determine treatment eligibility. By measuring and comparing these molecular parameters against established thresholds and patterns, the system dynamically adapts treatment recommendations to match the patient's molecular profile, enabling precision medicine approaches for MASLD.
Data Source
AI summary
An application of a biomarker in preparing metabolic dysfunction-associated steatotic liver disease classification products is provided. The biomarker is any one or more of the following: a combination of liver protein biomarkers, a combination of serum protein biomarkers, a combination of serum lipid biomarkers, a combination of serum metabolite biomarkers, a combination of serum protein, lipid and metabolite biomarkers, a combination of urine protein biomarkers, a combination of urine metabolite biomarkers, and a combination of urine protein and metabolite biomarkers; and the metabolic dysfunction-associated steatotic liver disease is divided into a metabolically active type, a high-risk type of cirrhosis and a high-risk type of hepatocellular carcinoma. The combinations of biomarkers provided by the present disclosure have a good effect on the diagnosis of three MASLD molecular subtypes, which provides technical support for the classification and diagnosis of MASLD.